Literature DB >> 194908

Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: effect on calcium and parathyroid status.

F Llach, J W Coburn, A S Brickman, K Kurokawa, A W Norman, J M Canterbury, E Reiss.   

Abstract

The present study was undertaken to evaluate the acute effect of 1,25-dihydroxy-vitamin D3 (1,25 (OH)2D3) on serum Ca, P and immunoreactive parathyroid (iPTH) and urinary Ca, P. and cyclic AMP. In 8 normal subjects, samples were collected over intervals of 30 to 60 min during a control day and on a treatment day following oral ingestion of 1,25(OH)2D3, 2.7 microgram. For the entire group there were no significant changes in serum Ca. P, iPTH or urinary P. Urinary Ca increased significantly 7 h after administration of 1,25(OH)2D3, and urinary cAMP decreased at 12 h. In 4 patients (group A). showing an increase in serum Ca by 0;2 to 0.4 mg/dl, serum iPTH decreased in 3, and the decrease in urinary cAMP appeared sooner. Among 4 patients showing no change in serum Ca after 1,25(HO)2D3 (group B), 3 showed an increase in iPTH. These data document the early onset of action of 1,25(OH)2D3 following its administration to normal man; increments in urinary Ca provide the most sensitive index of its action. The data provide no support for the view that 1,25(OH)2D3 exerts any direct inhibitory effect on the secretion of parathyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194908     DOI: 10.1210/jcem-44-6-1054

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Interactions between vitamin D deficiency and phosphorus depletion in the rat.

Authors:  N Brautbar; M W Walling; J W Coburn
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

2.  The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells.

Authors:  Y L Chan; C McKay; E Dye; E Slatopolsky
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

3.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Inhibition by 1,25 dihydroxycholecalciferol of hormonal secretion of rat parathyroid gland in organ culture.

Authors:  W Y Au
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

5.  Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Authors:  J M Canterbury; S Lerman; A J Claflin; H Henry; A Norman; E Reiss
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

6.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Authors:  E Slatopolsky; C Weerts; J Thielan; R Horst; H Harter; K J Martin
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

7.  Effects of 1,25 dihydroxyvitamin D3 administration on circadian mineral rhythms in humans.

Authors:  M E Markowitz; J F Rosen; M Mizruchi
Journal:  Calcif Tissue Int       Date:  1985-07       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.